Elderly patients presenting with more advanced BC, partly due to the lack of systemic screening [5,6], have higher rates of ER-positive/HER2-negative phenotypes than younger cohorts, such as those included in pivotal studies [7], with higher rates of triple-negative (TN) BC and HER2-positive BC in young (≤40 years old) and very young (≤35 years old) patients [8]. Here, ERBB2 is linked to breast cancer.